Navigation Links
Global Pharmaceutical R&D Productivity Declining According to Thomson Reuters, CMR International
Date:6/27/2010

PHILADELPHIA and LONDON, June 28 /PRNewswire/ -- The pharmaceutical industry continues to rely heavily on sales from an aging portfolio of drugs, whilst the proportion of total sales from newer drugs has dropped, according to data released today from the 2010 Pharmaceutical R&D Factbook complied by CMR International, a Thomson Reuters business.

The new edition of the R&D Factbook shows that the majority of sales for the world's leading pharmaceutical companies are derived from the most mature drugs, with the top three drugs for a company on average contributing 44 percent of total sales.  

A general decline in success rates for new drugs also has taken its toll on productivity and indicative of this is a doubling of phase III terminations in the period 2007-2009 compared with those in 2004-2006. Further analysis of the data reveals that less than 1 in 10 drugs reaching 'first toxicity dose' can now expect to be successfully launched.  

Key highlights from the 2010 R&D Factbook include:

  • The proportion of total sales from drugs launched within the last five years has dropped to below 7 percent, compared with 8 percent in 2008.  
  • R&D expenditure dropped by 0.3 percent in 2009, down from 6.6 percent in 2008, and in stark contrast to the growth rate of previous years.
  • 26 new molecular entities (NME) were launched onto the global market in 2009, an increase from 2008's 20-year low of 21.
  • 17.9 percent of global R&D expenditure was allocated to anti-cancer drugs, making it the therapeutic area receiving the largest proportion of investment.
  • Competition from the generics sector is increasing in particular due to contributions from
    '/>"/>

SOURCE Thomson Reuters
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reportlinker Adds Global Medical Device Outsourcing Industry
2. Reportlinker Adds Global Hernia Repair Devices Industry
3. Reportlinker Adds Global Bipolar Disorder Industry
4. Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
5. Henry Schein to Present at the Goldman Sachs 31st Annual Global Healthcare Conference
6. DHL Global Mail Launches Specialized Shipping Service for Mail-Order Pharmacies
7. Perrigo Company to Present at the 31st Annual Goldman Sachs Global Healthcare Conference
8. Covance to Present at Goldman Sachs 31st Annual Global Healthcare Conference
9. Nonin Medical Introduces Latest Generation of Veterinary Handheld Pulse Oximeter for Global Distribution
10. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
11. Kensey Nash to Present at the Jefferies 2010 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... REDWOOD CITY, Calif. , Oct. 22, 2014 ... ) today announced that results from the  IAP310 ... and Pain Medicine (RAPM), a peer-reviewed journal ... placebo-controlled, Phase 3 trial evaluating the safety and ... sufentanil sublingual tablet system (SSTS), for the treatment ...
(Date:10/22/2014)... 22, 2014  Regulus Therapeutics Inc. (NASDAQ: ... leading the discovery and development of innovative ... has demonstrated human proof-of-concept with a microRNA ... RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ... virus infection ("HCV").  Interim results from the ...
(Date:10/20/2014)... VIEW, Calif. , Oct. 20, 2014  PneumRx, ... of interventional pulmonology, today announced completion of enrollment in ... The RENEW Clinical Study is the FDA-approved IDE pivotal ... for severe emphysema. It was anticipated that ... in February 2013, would take until the end of ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. 20, 2014 (HealthDay ... for health workers treating Ebola patients, now requiring full body ... at all times. The U.S. Centers for Disease Control ... Dallas nurses contracted Ebola while caring for the first ... Duncan. Nina Pham is currently being treated for her infection ...
(Date:10/20/2014)... October 20, 2014 The newly updated ... source of thousands of facts, figures and forecasts on ... 68 medical sector forecast categories the Worldwide Medical ... regional and national views on the worldwide medical market ... The report gives you data for 2010-2019, covering each ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is offering ... a damaged mitral valve as the heart continues to ... Abbott Vascular , is designed to treat degenerative ... which the heart’s mitral valve leaflets fail to close ... left ventricle into the left atrium. The heart must ...
(Date:10/20/2014)... York, NY (PRWEB) October 20, 2014 ... based non-profit organization that helps New Yorkers living ... positive changes toward health, housing, recovery and self-sufficiency. ... have transformed the local community through their tireless ... Director, Marc Shapses , has been selected ...
(Date:10/20/2014)... ATLANTA, Ga. (PRWEB) October 20, 2014 ... networking and relationship-marketing firm, announced today that William ... been named the 2014 ISE® Luminary Leadership Award ... celebrates the achievements of an outstanding leader and ... stewardship and contributions in advancing the information security ...
Breaking Medicine News(10 mins):Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... ... Jan Linhart reveals health benefits of orthodontics , ... New York, NY (Vocus) June 25, 2009 -- Dr. Jan Linhart, a ... but also to a patient’s health. , ,"While orthodontic procedures such as Invisalign and ...
... Verizon Business, Fully Managed Solution Provides Secure Foundation for ... PARIS, June 25 Invacare Corp., a ... has chosen Verizon Business to deploy and manage its ... IP solution effectively quadruples the bandwidth available to employees ...
... ... physicians, Jackson & Coker has helped sponsor several "medical brigades" visiting Honduras to perform ... ... Tapping the growing interest in medical volunteerism shown by many locum tenens physicians, Jackson ...
... Many parents worry about their child,s exposure to phthalates, the ... personal care products, children,s toys, and medical devices. Phthalate ... with negative changes in endocrine function. A new study ... examines the possibility that in utero phthalate exposure contributes ...
... , June 24 Siemens Healthcare ( ... Thomas Miller, Chief Executive Officer (CEO) for the Workflow & ... on Energy and Commerce, U.S. House of Representatives on the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ) , ...
... recognized children,s health-care leader, may be faced with harsh decisions ... G. Rendell said today that Pennsylvania families should not have ... especially during hard economic times -- and urged the General ... the upcoming state budget. , , "The nation is ...
Cached Medicine News:Health News:Top Dentist Issues Opinion on Health Benefits of Cutting-Edge Orthodontics 2Health News:Verizon Private IP Quadruples Network Capacity for Invacare's European Operations 2Health News:Verizon Private IP Quadruples Network Capacity for Invacare's European Operations 3Health News:Jackson & Coker Sponsors Medical Missions 2Health News:Jackson & Coker Sponsors Medical Missions 3Health News:Siemens Healthcare Testifies on Healthcare Reform and Building a Healthier America 2Health News:Siemens Healthcare Testifies on Healthcare Reform and Building a Healthier America 3Health News:Pennsylvania Governor Rendell Urges General Assembly to Support Children's Health Insurance Program 2
This storage freezer, which is based on our premium freezer line, maintain red cells safely below regulatory standards at -86C (-123F). Recorder is standard for model 8627. Model 8627 is UL Listed, C...
... the precise requirements of blood banking ... Bank Equipment meets American Association of ... Cross (ANRC) and U.S. Food & ... freezers, and platelet incubators feature alarm ...
... Designed for the precise requirements ... Thermo Forma Blood Bank Equipment meets ... American National Red Cross (ANRC) and ... standards. Refrigerators, storage freezers, and platelet ...
... This refrigerator is specially ... of blood in standard ... Australian Standard AS3864 1997. ... air-cooled utilising CFC Free ...
Medicine Products: